Profile data is unavailable for this security.
About the company
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
- Revenue in USD (TTM)197.71m
- Net income in USD-17.56m
- Incorporated2014
- Employees645.00
- LocationCytek Biosciences Inc47215 LAKEVIEW BOULEVARDFREMONT 94538United StatesUSA
- Websitehttps://cytekbio.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pacific Biosciences of California Inc | 188.87m | -400.38m | 555.96m | 796.00 | -- | 1.13 | -- | 2.94 | -1.50 | -1.50 | 0.7099 | 1.81 | 0.1125 | 2.05 | 6.69 | 237,275.10 | -23.85 | -16.19 | -26.63 | -17.81 | 26.01 | 37.35 | -211.99 | -136.21 | 7.14 | -22.46 | 0.6444 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Surmodics Inc | 120.82m | -1.40m | 557.71m | 376.00 | -- | 4.76 | 76.26 | 4.62 | -0.0955 | -0.0955 | 8.55 | 8.28 | 0.6597 | 2.09 | 5.64 | 321,332.40 | -0.7638 | -1.85 | -0.8909 | -2.18 | 74.02 | 82.93 | -1.16 | -2.98 | 3.22 | -4.46 | 0.1999 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| Paragon 28 Inc | 235.44m | -59.07m | 574.51m | 430.00 | -- | 3.91 | -- | 2.44 | -0.7132 | -0.7132 | 2.84 | 1.76 | 0.7703 | 0.6049 | 6.63 | 547,539.60 | -19.33 | -- | -23.48 | -- | 76.67 | -- | -25.09 | -- | 1.70 | -5.30 | 0.4295 | -- | 19.30 | -- | 28.94 | -- | -- | -- |
| Quanterix Corp | 129.33m | -39.71m | 594.49m | 441.00 | -- | 1.77 | -- | 4.60 | -1.04 | -1.04 | 3.40 | 8.77 | 0.3078 | 2.37 | 4.60 | 293,265.30 | -9.45 | -15.96 | -10.30 | -17.66 | 57.42 | 52.79 | -30.71 | -53.79 | 8.99 | -- | 0.00 | -- | 15.96 | 26.60 | 66.56 | -- | 20.07 | -- |
| Orthofix Medical Inc | 771.65m | -120.49m | 611.73m | 1.63k | -- | 1.14 | -- | 0.7928 | -3.21 | -3.21 | 20.55 | 14.35 | 0.8654 | 1.17 | 6.49 | 472,245.40 | -13.51 | -8.88 | -16.22 | -10.96 | 67.18 | 72.37 | -15.62 | -9.28 | 1.13 | -4.94 | 0.2005 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Iradimed Corp | 69.48m | 18.64m | 623.73m | 148.00 | 33.65 | 7.83 | 32.04 | 8.98 | 1.46 | 1.46 | 5.45 | 6.29 | 0.8109 | 1.55 | 6.03 | 469,485.30 | 21.76 | 13.16 | 23.85 | 14.58 | 77.21 | 76.55 | 26.83 | 21.46 | 8.25 | 144.05 | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| AxoGen Inc | 173.48m | -16.54m | 642.98m | 426.00 | -- | 6.72 | -- | 3.71 | -0.3829 | -0.3829 | 4.01 | 2.18 | 0.9117 | 1.62 | 7.43 | 407,237.10 | -8.69 | -13.92 | -9.93 | -15.84 | 76.98 | 79.74 | -9.53 | -20.28 | 2.32 | -2.94 | 0.3297 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Simulations Plus Inc | 66.98m | 9.65m | 645.45m | 192.00 | 68.05 | 3.57 | 45.64 | 9.64 | 0.474 | 0.474 | 3.29 | 9.04 | 0.3603 | -- | 5.57 | 348,843.80 | 5.19 | 7.20 | 5.49 | 7.61 | 72.53 | 77.61 | 14.40 | 21.29 | -- | -- | 0.00 | 45.70 | 10.52 | 14.96 | -20.20 | 6.02 | 12.91 | 0.8548 |
| SI-Bone Inc | 150.71m | -40.85m | 660.02m | 344.00 | -- | 3.99 | -- | 4.38 | -1.00 | -1.00 | 3.70 | 3.97 | 0.6586 | 1.54 | 6.67 | 438,107.60 | -17.85 | -27.88 | -19.57 | -30.94 | 77.69 | 85.03 | -27.10 | -51.09 | 8.12 | -- | 0.18 | -- | 30.52 | 20.19 | 29.25 | -- | 52.62 | -- |
| Mesa Laboratories Inc | 223.71m | -250.31m | 694.70m | 736.00 | -- | 4.61 | -- | 3.11 | -46.43 | -46.43 | 41.43 | 27.87 | 0.4131 | 2.51 | 6.29 | 303,956.50 | -46.23 | -9.20 | -50.62 | -9.88 | 62.27 | 60.60 | -111.89 | -28.33 | 1.37 | 1.33 | 0.5848 | -- | -1.32 | 15.95 | -27,438.28 | -- | 15.26 | 0.00 |
| Cytek Biosciences Inc | 197.71m | -17.56m | 695.66m | 645.00 | -- | 1.79 | -- | 3.52 | -0.1327 | -0.1327 | 1.49 | 2.96 | 0.392 | 1.54 | 4.19 | 292,470.40 | -3.48 | -- | -3.89 | -- | 54.97 | -- | -8.88 | -- | 6.38 | -- | 0.0083 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
| Orthopediatrics Corp | 175.07m | -25.12m | 707.30m | 247.00 | -- | 1.91 | -- | 4.04 | -1.10 | -1.10 | 7.65 | 15.33 | 0.4045 | 0.4286 | 4.61 | 708,793.50 | -5.80 | -5.40 | -6.43 | -5.93 | 74.62 | 75.09 | -14.35 | -15.92 | 1.96 | -44.23 | 0.0261 | -- | 21.62 | 20.91 | -1,767.25 | -- | 28.29 | -- |
| Standard Biotools Inc | 136.30m | -164.66m | 783.14m | 534.00 | -- | 1.53 | -- | 5.75 | -0.9018 | -0.9018 | 0.6606 | 1.37 | 0.2561 | 2.25 | 5.73 | 255,243.50 | -22.29 | -28.17 | -26.55 | -33.60 | 46.67 | 51.58 | -87.05 | -74.85 | 3.53 | -- | 0.0974 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
| Castle Biosciences Inc | 287.59m | -3.10m | 846.80m | 610.00 | -- | 2.00 | 84.79 | 2.94 | -0.1346 | -0.1346 | 10.45 | 15.30 | 0.6302 | 7.38 | 7.44 | 471,457.40 | -0.6791 | -9.43 | -0.7383 | -10.17 | 81.86 | 80.58 | -1.08 | -28.46 | 7.92 | -- | 0.0238 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Alphatec Holdings Inc | 540.28m | -180.91m | 872.26m | 839.00 | -- | 51.90 | -- | 1.61 | -1.34 | -1.34 | 4.00 | 0.2847 | 0.7736 | 1.13 | 7.30 | 643,959.50 | -25.90 | -30.97 | -33.24 | -39.47 | 69.44 | 66.02 | -33.48 | -46.22 | 1.21 | -4.59 | 0.9273 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
| Embecta Corp | 1.12bn | 69.70m | 906.50m | 2.20k | 13.02 | -- | 8.37 | 0.8102 | 1.21 | 1.21 | 19.36 | -13.24 | 0.8882 | 2.11 | 11.60 | 508,590.90 | 5.53 | -- | 7.91 | -- | 66.42 | -- | 6.23 | -- | 1.61 | 2.06 | 1.88 | -- | -0.7703 | -- | -68.52 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Cytek Biosciences Inc's reporting currency: US Dollar USD
45.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 15.83m | 12.04% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 11.57m | 8.80% |
| Brown Capital Management LLCas of 30 Jun 2024 | 11.39m | 8.66% |
| HHLR Advisors Ltd.as of 30 Jun 2024 | 6.66m | 5.06% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 3.97m | 3.02% |
| New York State Common Retirement Fundas of 30 Jun 2024 | 2.95m | 2.24% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.58m | 1.96% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 2.14m | 1.62% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 1.34m | 1.02% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 1.07m | 0.82% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
